September 11, 2001 goes down in history as one of the most tragic events in human history. Today, StocksHaven Investments pays its respects to the innocent and fallen heroes which passed away. Gone, but never forgotten. God Bless.

Nutra Pharma Corp. (Public, OTC:NPHC) Step aside Morphine, the new king of chronic pain treatment has entered the building. With Nutra Pharma’s stock rising nearly 2300% year-to-date, its time we see what all the commotion is about. StocksHaven Investments takes a closer look at Nutra Pharma Corp., which believes will begin generating significant revenues within [...]

Muscle Flex, Inc (Public, OTC:MFLI) The following article is submitted by a well experienced private investment group(Farseers) members Mr. Nukala and Mr. Sekona closely working with Stockshaven Investments, which conducted a recent conference call with Danny Alex the CEO of Muscle Flex Inc. Mr. Nukala is also a member of Cohen Investment Group, http://www.cohenresearch.com with [...]

In order to facilitate greater savings and increase financial solidity, many consumers have traditionally turned to savings accounts. There are many different kinds of savings accounts out there that can offer benefits. However, in the current economic situation, other options might be more appealing than placing your money within one of the many national banks [...]

Tired of missing out on MiV Investments Inc. newest picks? Well now you don’t have to worry. We have recently just put together a special distribution list, and best of all – It’s FREE! Advantages: * Receive alerts well before articles are published & PR’d * Company basics & fundamentals will be provided * Speak [...]

GenVec, Inc. (Public, NASDAQ:GNVC) StocksHaven Investments profiles a clinical stage biopharmaceutical company developing gene-based therapeutic drugs and vaccines. Its lead product candidate, TNFerade biologic (TNFerade), is being developed for use in the treatment of cancer, and is currently undergoing Phase III trials which are expected to be completed by Q1 2010. In addition to its [...]

Adeona Pharmaceuticals, Inc. (Public, AMEX:AEN) StocksHaven Investments takes a look at Adeona Pharmaceuticals, Inc. which currently has three blockbuster drugs in phase III, and are coming close to NDA status. The first being Trimesta, which tackles Multiple Sclerosis (MS) and Post-partum Depression. Secondly, Zinthionein, a product seeking treatment for Age Related Macular Degeneration (AMD). Lastly, [...]

Nutra Pharma Corp. (Public, OTC:NPHC) StocksHaven Investments has confirmed they are set to profile Nutra Pharma Corp. in the coming days, and states that they have also touched base with with Investor Relations in regards to scheduling a tentative conference call with the Chairman and CEO, Rik J Deitsch. Nutra Pharma has recently made waves [...]

Power3 Medical Products, Inc. (Public, OTC:PWRM) The following company analysis has been contributed by a StocksHaven Investments affiliate and member, Michael Sklar. He has been studying the markets for several years now with a focus in undiscovered Bio-Pharm companies. About Power3 Medical Products, Inc. (Power3) is primarily engaged in commercializing its intellectual properties in the [...]

Derma Sciences, Inc. (Public, OTC:DSCI) Derma Sciences is a truly unique and highly undervalued company within the micro-cap biomed space which currently targets a prescription drug market that is about 5x its present market cap. The company is developing a patented topical drug for accelerated healing and scar prevention and newly launched Advanced Wound Care [...]